Notifications and Recalls

Generic Name (Trade Name—Company) | Uses/Notes
--- | ---
November 29, 2018 | 

**Enasidenib**

FDA is warning that signs and symptoms of a life-threatening adverse effect called differentiation syndrome are not being recognized in patients receiving the acute myeloid leukemia medicine enasidenib. The enasidenib prescribing information and patient Medication Guide already contain a warning about differentiation syndrome. However, the agency said it has become aware of cases of differentiation syndrome not being recognized and patients not receiving the necessary treatment.

As a result, FDA is alerting health professionals and patients about the need for early recognition and aggressive management of differentiation syndrome to lessen the likelihood of serious illness and death. The agency is continuing to monitor this safety concern.

Health professionals should describe to patients the symptoms of differentiation syndrome listed in the Medication Guide when starting enasidenib and at follow-up visits, and inform them to call their health professional if such symptoms occur. Differentiation syndrome has occurred as early as 10 days and up to 5 months after starting the medicine. If patients experience unexplained respiratory distress or other symptoms, consider a diagnosis of differentiation syndrome, and treat promptly with oral or I.V. corticosteroids.

Patients should contact their health professional or go to the nearest hospital emergency department right away if they develop any of the following symptoms of differentiation syndrome while taking enasidenib: fever; cough; shortness of breath; swelling of arms and legs; swelling around the neck, groin, or underarm area; fast weight gain of more than 10 pounds within a week; bone pain; or feeling dizzy or lightheaded.

Enasidenib was approved in August 2017 to treat patients with acute myeloid leukemia (AML) with a specific genetic mutation called isocitrate dehydrogenase (IDH)-2 whose disease has come back or has not improved after treatment with other chemotherapy medicines. Enasidenib works by blocking
several enzymes that promote this abnormal blood cell growth.

In the clinical trial conducted for enasidenib's approval, at least 14% of patients experienced differentiation syndrome. The manufacturer’s safety report, which included the period of May 1, 2018, to July 31, 2018, reported five cases of death associated with differentiation syndrome in patients taking the drug.

Health professionals urged to recognize symptoms of life-threatening differentiation syndrome in patients taking leukemia drug

Source URL:

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.